---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038400"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:29:39.789507+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma issues $40K convertible note to 1800 Diagonal Lending

## Summary
- Principal $40,000, convertible at 65% of lowest three trading prices in prior ten trading days.
- Interest 8% per annum (22% on default); maturity October 20, 2024.
- Company may prepay at 110%-129% premium within first 180 days; no prepayment after that.
- Proceeds used for general working capital; funds not yet received as of filing date.
- Conversion subject to 4.99% beneficial ownership limitation; 500% initial share reserve required.

## SEC filing metadata
- accession: 0001493152-23-038400
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223038400/0001493152-23-038400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223038400/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038400
- JSON: https://secwatch.observer/filing/0001493152-23-038400.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038400.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $40,000 with an investor at 8% per annum, which may be increased to 22% in the event of a default maturing October 20, 2024.
  - Instrument: convertible notes
  - Principal: $40,000
  - Counterparty: an investor
  - Rate: 8% per annum, which may be increased to 22% in the event of a default
  - Maturity: October 20, 2024
  - Event: incurrence
  source text: On October 20, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $40,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223038400/0001493152-23-038400-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the "Investor") valued at $40,000 (effective 2023-10-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an investor (the "Investor")
  - Value: $40,000
  - Effective: 2023-10-20
  source text: On October 20, 2023, Propanc Biopharma, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with an investor (the "Investor"), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $40,000 (the "Note")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223038400/0001493152-23-038400-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.